Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder
J Clin Psychiatry 2005;66(10):1216-1220
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: To determine the efficacy and
tolerability of aripiprazole, a dopamine
D2 and 5-HT1A receptor partial agonist, as augmentation of
antidepressant treatment of partially responding
and nonresponding patients with major depressive disorder.
Method: Fifteen patients with major
depressive disorder (diagnosed with a
site-generated form described in the text) and an
incomplete response or no response to >= 8 weeks of
antidepressant (selective serotonin reuptake
inhibitor, venlafaxine, or bupropion) monotherapy
were treated with aripiprazole augmentation in an
8-week, open-label study. Data were gathered from July 2003 to March 2004.
Results: The mean duration of
antidepressant monotherapy at baseline was 43.1 weeks.
At baseline, mean Clinical Global Impressions-Severity of Illness scale and Hamilton Rating
Scale for Depression (HAM-D) scores were 4.3 and 18.9, respectively. After initiation of
aripiprazole augmentation, 6 of 15 patients achieved
remission (HAM-D score <= 7) at week 1, and 9 of 15
patients remitted by week 2. All 8 completers achieved remission by study endpoint. Akathisia in 2 patients who withdrew prematurely
prompted a reduction in the starting dose of
aripiprazole from 10 mg/day to 2.5 mg/day, resulting in a
50% reduction in attrition due to akathisia (2/7
withdrew due to akathisia with the 10-mg starting dose, 1/8 withdrew due to akathisia with the
2.5-mg starting dose). Discontinuation rates after
4 weeks of treatment were lower for the 2.5-mg starting dose (1/8 patients) than for the
10-mg starting dose (3/7 patients). Overall
discontinuation rates at endpoint were lower for the
2.5-mg dose (3/8 patients) than the 10-mg dose (4/7
patients). Response to aripiprazole augmentation did not appear to be related to the
antidepressant used at study initiation.
Conclusion: Aripiprazole is an effective
augmentation strategy for improving therapeutic response in patients with treatment-resistant
major depressive disorder when administered in
combination with standard antidepressant therapy. Based on this clinical signal, a double-blind,
placebo-controlled trial is warranted.